These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

710 related articles for article (PubMed ID: 30628518)

  • 41. Uveitis and hypereosinophilia associated with dupilumab in an atopic dermatitis patient.
    Zhang S; Lu L; Feng J; Hu Z; Song H; Yang L; Liu Y; Chen D; Wang T
    J Dermatolog Treat; 2023 Dec; 34(1):2229466. PubMed ID: 37369546
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Psoriasis in dupilumab-treated atopic dermatitis].
    Senner S; Eicher L; Aszodi N; Prinz JC; French LE; Wollenberg A
    Hautarzt; 2020 May; 71(5):383-386. PubMed ID: 32179945
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Dupilumab treatment in adults with moderate-to-severe atopic dermatitis.
    Beck LA; Thaçi D; Hamilton JD; Graham NM; Bieber T; Rocklin R; Ming JE; Ren H; Kao R; Simpson E; Ardeleanu M; Weinstein SP; Pirozzi G; Guttman-Yassky E; Suárez-Fariñas M; Hager MD; Stahl N; Yancopoulos GD; Radin AR
    N Engl J Med; 2014 Jul; 371(2):130-9. PubMed ID: 25006719
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Dupilumab for the treatment of refractory allergic contact dermatitis from rubber/latex concomitant with atopic dermatitis.
    Koh YG; Park JW; Shin SH; Kim BJ; Yoo KH
    J Eur Acad Dermatol Venereol; 2022 Aug; 36(8):e640-e643. PubMed ID: 35338674
    [No Abstract]   [Full Text] [Related]  

  • 45. Eye Complications During Dupilumab Treatment for Severe Atopic Dermatitis.
    Ivert LU; Wahlgren CF; Ivert L; Lundqvist M; Bradley M
    Acta Derm Venereol; 2019 Apr; 99(4):375-378. PubMed ID: 30653240
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Attenuating the atopic march: Meta-analysis of the dupilumab atopic dermatitis database for incident allergic events.
    Geba GP; Li D; Xu M; Mohammadi K; Attre R; Ardeleanu M; Musser B
    J Allergy Clin Immunol; 2023 Mar; 151(3):756-766. PubMed ID: 36084766
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Dupilumab facial redness: histologic characterization on a series of four cases.
    Dybała A; Sernicola A; Gomes V; Carnicelli G; Muharremi R; Grieco T
    Immunotherapy; 2022 Mar; 14(4):183-188. PubMed ID: 34933583
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Dupilumab shows long-term safety and efficacy in patients with moderate to severe atopic dermatitis enrolled in a phase 3 open-label extension study.
    Deleuran M; Thaçi D; Beck LA; de Bruin-Weller M; Blauvelt A; Forman S; Bissonnette R; Reich K; Soong W; Hussain I; Foley P; Hide M; Bouaziz JD; Gelfand JM; Sher L; Schuttelaar MLA; Wang C; Chen Z; Akinlade B; Gadkari A; Eckert L; Davis JD; Rajadhyaksha M; Staudinger H; Graham NMH; Pirozzi G; Ardeleanu M
    J Am Acad Dermatol; 2020 Feb; 82(2):377-388. PubMed ID: 31374300
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Morphea after initiation of dupilumab in two pediatric atopic dermatitis patients.
    Wang S; Berry CT; Treat JR; Jen M
    Pediatr Dermatol; 2023; 40(3):540-543. PubMed ID: 37212737
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Adverse events of Dupilumab in adults with moderate-to-severe atopic dermatitis: A meta-analysis.
    Ou Z; Chen C; Chen A; Yang Y; Zhou W
    Int Immunopharmacol; 2018 Jan; 54():303-310. PubMed ID: 29182975
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis.
    Simpson EL; Bieber T; Guttman-Yassky E; Beck LA; Blauvelt A; Cork MJ; Silverberg JI; Deleuran M; Kataoka Y; Lacour JP; Kingo K; Worm M; Poulin Y; Wollenberg A; Soo Y; Graham NM; Pirozzi G; Akinlade B; Staudinger H; Mastey V; Eckert L; Gadkari A; Stahl N; Yancopoulos GD; Ardeleanu M;
    N Engl J Med; 2016 Dec; 375(24):2335-2348. PubMed ID: 27690741
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Dupilumab for Atopic Dermatitis, a Possible Risk Factor of Juvenile Ischemic Stroke: A Case Report.
    Iwase R; Ishiguro T; Fujita K; Ishibashi S; Yokota T
    J Stroke Cerebrovasc Dis; 2020 Jun; 29(6):104763. PubMed ID: 32265139
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Development of systemic lupus erythematosus after dupilumab treatment in a case of atopic dermatitis.
    Okune M; Okiyama N; Fukuzono M; Sasaki K; Nomura T
    J Dermatol; 2022 May; 49(5):556-559. PubMed ID: 35224748
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Facial erythema in patients with atopic dermatitis treated with Dupilumab - a descriptive study of morphology and Aetiology.
    Ahn J; Lee DH; Na CH; Shim DH; Choi YS; Jung HJ; Simpson EL
    J Eur Acad Dermatol Venereol; 2022 Nov; 36(11):2140-2152. PubMed ID: 35695074
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A paradoxical head and neck erythema: an adverse event due to dupilumab in adult patients with atopic dermatitis.
    Russo F; Rizzo A; Santi F; Lamberti A; Lazzeri L; Flori ML; Rubegni P
    Int J Dermatol; 2022 Jun; 61(6):e204-e206. PubMed ID: 34480761
    [No Abstract]   [Full Text] [Related]  

  • 56. Development of conjunctivitis with a conjunctival proliferative lesion in a patient treated with dupilumab for atopic dermatitis.
    Fukuda K; Ishida W; Kishimoto T; Fukushima A
    Allergol Int; 2019 Jul; 68(3):383-384. PubMed ID: 30718036
    [No Abstract]   [Full Text] [Related]  

  • 57. Recall dermatitis at patch test sites in an atopic dermatitis patient treated with dupilumab.
    Collantes-Rodríguez C; Jiménez-Gallo D; Ossorio-García L; Villegas-Romero I; Linares-Barrios M
    Contact Dermatitis; 2019 Jan; 80(1):69-70. PubMed ID: 30334260
    [No Abstract]   [Full Text] [Related]  

  • 58. Dupilumab and the risk of conjunctivitis and serious infection in patients with atopic dermatitis: A propensity score-matched cohort study.
    Schneeweiss MC; Kim SC; Wyss R; Schneeweiss S; Merola JF
    J Am Acad Dermatol; 2021 Feb; 84(2):300-311. PubMed ID: 33038471
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Type 2 Inflammation: Atopic Dermatitis, Asthma, and Hypereosinophilia Successfully Treated With Dupilumab.
    Benzecry V; Pravettoni V; Segatto G; Marzano AV; Ferrucci S
    J Investig Allergol Clin Immunol; 2021 Jun; 31(3):261-263. PubMed ID: 32732182
    [No Abstract]   [Full Text] [Related]  

  • 60. Dupilumab-associated ocular manifestations: A review of clinical presentations and management.
    Wu D; Daniel BS; Lai AJX; Wong N; Lim DKA; Murrell DF; Lim BXH; Mehta JS; Lim CHL
    Surv Ophthalmol; 2022; 67(5):1419-1442. PubMed ID: 35181280
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 36.